Evidence map›Paper›PMID 41200415›Full record

ArticleGMS hygiene and infection control2025

Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations.

Kazi-Chishti Marzooka, Shaikh Sajed, Mohamed Hassan Dehghan, Kazi Bilal, Rumani Imaan

Abstract read
In one paragraph

Article in GMS hygiene and infection control, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kazi-Chishti MarzookaDepartment of Pharmaceutics, Maulana Azad Educational Trust's, Y. B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Aurangabad, Maharashtra, India.
Shaikh SajedDepartment of Pharmaceutics, Maulana Azad Educational Trust's, Y. B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Aurangabad, Maharashtra, India.
Mohamed Hassan DehghanDepartment of Pharmaceutics, Maulana Azad Educational Trust's, Y. B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Aurangabad, Maharashtra, India.
Kazi BilalDepartment of Hematology, Bone Marrow Transplantation and Cellular Therapy, SunAct Cancer Institute, Mumbai, India.
Rumani ImaanDepartment of Surgical Oncology, SunAct Cancer Institute, Mumbai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review explore the rise of multidrug-resistant (MDR) Gram-negative bacteria, highlighting β-lactamase inhibitor combinations as crucial therapeutic options. It examines β-lactam resistance mechanisms, established combinations (e.g., ticarcillin/clavulanic acid, piperacillin/tazobactam), and the clinical efficacy of newer therapies like ceftazidime/avibactam (CAZ-AVI) for carbapenem-resistant

Indexed as

antibiotic resistancebeta-lactamase inhibitor combinationsgram-negative bacteria

Identifiers

PMID41200415
PMCPMC12587040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.